In RA, anti-TNF agents such as infliximab and adalimumab effectively suppress synovial inflammation and prevent joint destruction [5], while in PsA and psoriasis they also reduce cutaneous lesions and halt structural progression [6]. This evidence concerns the gene TNF and psoriasis.